Isaac Barchas, a director at Immunome Inc. (NASDAQ: IMNM), has completed a series of indirect sales of common stock totaling $4,393,024. The transactions were executed across multiple dates in late June and early July 2026, specifically on June 30 and July 2. These sales occurred within a price range of $21.12 to $23.33 per share. The timing of these divestments follows a substantial 167% gain in the stock over the past year, with the shares currently trading at $23.62. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, potentially explaining the decision to lock in gains at current levels.
The transactions were executed automatically pursuant to Rule 10b5-1 trading plans, which were adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B") on March 31, 2026. This structured approach ensures compliance with securities regulations by predetermining the terms of the trades.
On June 30, Mr. Barchas indirectly sold 101,050 shares of common stock at a weighted average price of $21.12 per share. These shares were sold by ABHMC (100,000 shares) and ABV II-B (1,050 shares). The prices for this specific transaction ranged from $20.83 to $21.47. Following this sale, 308,504 shares remained indirectly held.
On July 2, two additional indirect sales of common stock took place. The first involved 75,665 shares sold at a weighted average price of $22.35 per share, with prices ranging from $22.015 to $23.015. The second transaction on the same day saw 24,335 shares sold at a weighted average price of $23.33 per share, with prices ranging from $23.03 to $23.67. Both July 2 sales were conducted by ABHMC.
Following all reported transactions, Mr. Barchas indirectly holds 208,504 shares of Immunome common stock through ABHMC. Additionally, he directly holds 103,259 shares of common stock, which were received as pro rata distributions from Arsenal Bridge Venture II LLC for no additional consideration. Mr. Barchas serves as a managing member and holds a power of attorney with the ability to exercise voting and investment power over the shares held by ABHMC and ABV II-B, though he disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Wall Street analysts remain bullish on Immunome, with price targets ranging from $30 to $40, suggesting potential upside despite the recent insider sales. InvestingPro subscribers have access to 11 additional exclusive tips about IMNM, along with comprehensive financial health scores and Fair Value analysis.
In other recent news, Immunome Inc. has made several significant advancements. The company submitted a New Drug Application to the U.S. Food and Drug Administration for varegacestat, aimed at treating desmoid tumors. This submission follows the successful Phase 3 RINGSIDE trial, which demonstrated an 84% reduction in the risk of disease progression or death compared to placebo. Additionally, Immunome presented these trial results at the American Society of Clinical Oncology Annual Meeting, highlighting the promising outcomes. In another development, Immunome dosed the first patient in a Phase 1 trial of its antibody-drug conjugate, IM-1617, for solid tumors. Truist Securities raised its price target for Immunome to $37, maintaining a Buy rating, citing varegacestat’s potential in the desmoid tumor market. Meanwhile, Barclays initiated coverage of Immunome with an overweight rating and set a price target of $36, noting the company’s focus on ADC therapeutics. These developments mark a pivotal period for Immunome in its ongoing research and development efforts.